Literature DB >> 19446013

Down-regulation of 67LR reduces the migratory activity of human glioma cells in vitro.

F X Chen1, Y R Qian, Y H Duan, W W Ren, Y Yang, C C Zhang, Y M Qiu, Y H Ji.   

Abstract

OBJECTIVES: Glioma is the most common brain tumor in central nervous system. Traditional therapies are not effective to cure this disease. Experimental evidence indicates that the 67 kDa elastin-laminin receptor (67LR) subunit is a high-affinity non-integrin laminin-binding protein that is over-expressed on the tumor cell surface in a variety of human carcinomas, and directly correlates with a higher proliferation rate of malignant cells and tendency to metastasize. However, little is known of the expression and function of 67LR in glioma cells.
METHODS: In this study, we estimated whether 67LR was constitutively over-expressed in high-grade astrocytomas by immunohistochemical staining and Western blotting, and investigated the role of a low level of 67LR expression in glioma cell line-U251 by constructing an interfering RNA expression plasmid.
RESULTS: The results showed that the 67LR had an enhanced over-expression in high-grade astrocytomas against normal brain tissues samples, and that the migratory activity of glioma cells was reduced after the down-regulation of the 67LR gene by RNAi. DISCUSSION: It was hypothesized that a low level of 67LR expression could reduce migratory activity of glioma cells, which further proved that 67LR played an important role in glioma invasion by mediating tumor cell functions leading to sarcomata. This study provided a new alternative to gene therapy for glioma treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19446013     DOI: 10.1016/j.brainresbull.2009.04.019

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  7 in total

Review 1.  Looking into laminin receptor: critical discussion regarding the non-integrin 37/67-kDa laminin receptor/RPSA protein.

Authors:  Vincent DiGiacomo; Daniel Meruelo
Journal:  Biol Rev Camb Philos Soc       Date:  2015-01-28

2.  Epigallocatechin-3-gallate induces apoptosis, inhibits proliferation and decreases invasion of glioma cell.

Authors:  Hong Li; Zhe Li; Ya-Ming Xu; Yue Wu; Kang-Kang Yu; Can Zhang; Yong-Hua Ji; Gang Ding; Fu-Xue Chen
Journal:  Neurosci Bull       Date:  2013-12-13       Impact factor: 5.203

3.  Characterization of the ovine ribosomal protein SA gene and its pseudogenes.

Authors:  Alice Van den Broeke; Mario Van Poucke; Ane Marcos-Carcavilla; Karine Hugot; Hélène Hayes; Maud Bertaud; Alex Van Zeveren; Luc J Peelman
Journal:  BMC Genomics       Date:  2010-03-16       Impact factor: 3.969

4.  Down-regulation of Stat3 decreases invasion activity and induces apoptosis of human glioma cells.

Authors:  Fuxue Chen; Yaming Xu; Youqun Luo; Da Zheng; Yichao Song; Kangkang Yu; Hong Li; Li Zhang; Weiwei Zhong; Yonghua Ji
Journal:  J Mol Neurosci       Date:  2010-03       Impact factor: 3.444

5.  RNA interference-mediated silencing of laminin receptor 1 (LR1) suppresses migration and invasion and down-regulates matrix metalloproteinase (MMP)-2 and MMP-9 in trophoblast cells: implication in the pathogenesis of preeclampsia.

Authors:  Leilei Wang; Dan Zhang; Yang Yu; Hongbo Guan; Chong Qiao; Tao Shang
Journal:  J Mol Histol       Date:  2013-06-02       Impact factor: 2.611

6.  PED/PEA-15 interacts with the 67 kD laminin receptor and regulates cell adhesion, migration, proliferation and apoptosis.

Authors:  Pietro Formisano; Pia Ragno; Ada Pesapane; Daniela Alfano; Anna Teresa Alberobello; Vincenza Elena Anna Rea; Raffaella Giusto; Francesca W Rossi; Francesco Beguinot; Guido Rossi; Nunzia Montuori
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

7.  Synergetic downregulation of 67 kDa laminin receptor by the green tea (Camellia sinensis) secondary plant compound epigallocatechin gallate: a new gateway in metastasis prevention?

Authors:  Jakob Müller; Michael W Pfaffl
Journal:  BMC Complement Altern Med       Date:  2012-12-18       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.